Linked Life Data

20560878

Source:http://linkedlifedata.com/resource/pubmed/id/20560878

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-8-4
pubmed:abstractText
Earlier investigations from our laboratory demonstrated that the expression of matrix metalloproteinases (MMPs) was down-regulated by exogenously administered agmatine against ischemia-like injuries in the murine brain capillary endothelial (bEnd.3) cells. In our present study, we intended to investigate the mechanism involved in the inhibition of MMPs in bEnd.3 cells infected with retroviral containing human arginine decarboxylase (hADC) gene which can synthesize agmatine endogenously (ADCDeltabEnd.3 cells). The ADCDeltabEnd.3 cells were subjected to oxygen glucose deprivation (OGD, 6 hrs) with reperfusion (18 hrs). High performance liquid chromatography (HPLC) analysis revealed the high levels of agmatine in the ADCDeltabEnd.3 cells compared to other experimental groups. The results demonstrated significant decrease in cell death and increase in the nitric oxide (NO) production in the ADCDeltabEnd.3 cells. The increased expression of MMP-2 and MMP-9, and decreased expression of endothelial nitric oxide synthase (eNOS) by ischemic injury was attenuated in ADCDeltabEnd.3 cells. Moreover, the expression of activating transcription factor 3 (ATF3) was increased significantly in ADCDeltabEnd.3 cells. In addition, the suppression of the MMP-2 and MMP-9 expression in ADCDeltabEnd.3 cells was prevented with ATF3 small interfering RNA (siRNA) treatment. These results suggest that the endogenous agmatine in ADCDeltabEnd.3 cells inhibits the MMPs expression mediated via the regulation of eNOS, NO and ATF3.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1875-5739
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
201-12
pubmed:dateRevised
2011-6-7
pubmed:meshHeading
pubmed-meshheading:20560878-Activating Transcription Factor 3, pubmed-meshheading:20560878-Agmatine, pubmed-meshheading:20560878-Analysis of Variance, pubmed-meshheading:20560878-Animals, pubmed-meshheading:20560878-Blotting, Western, pubmed-meshheading:20560878-Brain, pubmed-meshheading:20560878-Cell Line, pubmed-meshheading:20560878-Cells, Cultured, pubmed-meshheading:20560878-Chromatography, High Pressure Liquid, pubmed-meshheading:20560878-Endothelium, Vascular, pubmed-meshheading:20560878-Immunohistochemistry, pubmed-meshheading:20560878-Matrix Metalloproteinases, pubmed-meshheading:20560878-Mice, pubmed-meshheading:20560878-Nitric Oxide, pubmed-meshheading:20560878-Nitric Oxide Synthase Type III, pubmed-meshheading:20560878-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:20560878-Transfection
pubmed:year
2010
pubmed:articleTitle
Endogenous agmatine inhibits cerebral vascular matrix metalloproteinases expression by regulating activating transcription factor 3 and endothelial nitric oxide synthesis.
pubmed:affiliation
BK 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't